2,190
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Glimpses into the molecular pathogenesis of Peyronie’s disease

, , , &
Pages 962-970 | Received 10 Jul 2019, Accepted 10 Jul 2019, Published online: 23 Jul 2019

References

  • Miner MM, Seftel AD. Peyronie's disease: epidemiology, diagnosis, and management. Curr Med Res Opin. 2014;30:113–120.
  • Dibenedetti DB, Nguyen D, Zografos L, et al. A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;2011:1.
  • Poullis C, Shabbir M, Eardley I, et al. Clostridium histolyticum collagenase – is this a revolutionary medical treatment for Peyronie's disease? BJU Int. 2016;118:186–189.
  • Sullivan J, Moskovic D, Nelson C, et al. Peyronie's disease: urologist's knowledge base and practice patterns. Andrology. 2015;3:260–264.
  • Sherer BA, Levine LA. Contemporary review of treatment options for Peyronie's disease. Urology. 2016;95:16–24.
  • Segal RL, Burnett AL. Surgical management for Peyronie's disease. World J Mens Health. 2013;31:1–11.
  • El-Sakka AI, Salabas E, Dincer M, et al. The pathophysiology of Peyronie's disease. Arab J Urol. 2013;11:272–277.
  • Nugteren HM, Nijman JM, de Jong IJ, et al. The association between Peyronie's and Dupuytren's disease. Int J Impot Res. 2011;23:142–145.
  • Carrieri MP, Serraino D, Palmiotto F, et al. A case–control study on risk factors for Peyronie's disease. J Clin Epidemiol. 1998;51:511–515.
  • Bjekic MD, Vlajinac HD, Sipetic SB, et al. Risk factors for Peyronie's disease: a case-control study. BJU Int. 2006;97:570–574.
  • Chammas M, Bousquet P, Renard E, et al. Dupuytren's disease, carpal tunnel syndrome, trigger finger, and diabetes mellitus. J Hand Surg Am. 1995;20:109–114.
  • Sommer F, Schwarzer U, Wassmer G, et al. Epidemiology of Peyronie's disease. Int J Impot Res. 2002;14:379–383.
  • Dolmans GH, Werker PM, Hennies HC, Dutch Dupuytren Study Group, German Dupuytren Study Group, LifeLines Cohort Study, BSSH-GODD Consortium, et al. Wnt signaling and Dupuytren's disease. N Engl J Med. 2011;365:307–317.
  • Ng M, Thakkar D, Southam L, et al. A genome-wide association study of Dupuytren disease reveals 17 additional variants implicated in fibrosis. Am J Hum Genet. 2017;101:417–427.
  • Hu FZ, Nystrom A, Ahmed A, et al. Mapping of an autosomal dominant gene for Dupuytren's contracture to chromosome 16q in a Swedish family. Clin Genet. 2005;68:424–429.
  • Nyberg LM Jr, Bias WB, Hochberg MC, et al. Identification of an inherited form of Peyronie's disease with autosomal dominant inheritance and association with Dupuytren's contracture and histocompatibility B7 cross-reacting antigens. J Urol. 1982;128:48–51.
  • Tomasek JJ, Schultz RJ, Haaksma CJ. Extracellular matrix-cytoskeletal connections at the surface of the specialized contractile fibroblast (myofibroblast) in Dupuytren disease. J Bone Joint Surg Am. 1987;69:1400–1407.
  • Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol. 2007;127:526–537.
  • Vernet D, Ferrini MG, Valente EG, et al. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model. Nitric Oxide. 2002;7:262–276.
  • Verjee LS, Midwood K, Davidson D, et al. Myofibroblast distribution in Dupuytren's cords: correlation with digital contracture. J Hand Surg Am. 2009;34:1785–1794.
  • Dolmans GH, Werker PM, de Jong IJ, et al. LifeLines Cohort Study, Wijmenga C, Ophoff RA. WNT2 locus is involved in genetic susceptibility of Peyronie's disease. J Sex Med. 2012;9:1430–1434.
  • Anderson ER, Ye Z, Caldwell MD, et al. SNPs previously associated with Dupuytren's disease replicated in a North American cohort. Clin Med Res. 2014;12:133–137.
  • Becker K, Siegert S, Toliat MR, et al. German Dupuytren Study Group. Meta-Analysis of Genome-Wide Association Studies and Network Analysis-Based Integration with Gene Expression Data Identify New Suggestive Loci and Unravel a Wnt-Centric Network Associated with Dupuytren's Disease. PLoS One. 2016;11:e0158101.
  • Chung E, Ralph D, Kagioglu A, et al. Evidence-based management guidelines on Peyronie's disease. J Sex Med. 2016;13:905–923.
  • Nesbit RM. Congenital curvature of the Phallus: report of three cases with description of corrective operation. Trans Am Assoc Genitourin Surg. 1964;56:20–22.
  • Yamauchi M, Sricholpech M. Lysine post-translational modifications of collagen. Essays Biochem. 2012;52:113–133.
  • Ten Dam EJ, van Beuge MM, Bank RA, et al. Further evidence of the involvement of the Wnt signaling pathway in Dupuytren's disease. J Cell Commun Signal. 2016;10:33–40.
  • van Beuge MM, Ten Dam EJ, Werker PM, et al. Wnt pathway in Dupuytren disease: connecting profibrotic signals. Transl Res. 2015;166:762–771.e3.
  • van Beuge MM, Ten Dam EJ, Werker PM, et al. Matrix and cell phenotype differences in Dupuytren's disease. Fibrogenesis Tissue Repair. 2016;9:9.
  • Gonzalez-Cadavid NF, Magee TR, Ferrini M, et al. Gene expression in Peyronie's disease. Int J Impot Res. 2002;14:361–374.
  • De Young LX, Bella AJ, O'Gorman DB, et al. Protein biomarker analysis of primary Peyronie's disease cells. J Sex Med. 2010;7:99–106.
  • Liu F, Lagares D, Choi KM, et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol. 2015;308:L344–L357.
  • Piersma B, de Rond S, Werker PM, et al. YAP1 Is a driver of myofibroblast differentiation in normal and diseased fibroblasts. Am J Pathol. 2015;185:3326–3337.
  • Mannaerts I, Leite SB, Verhulst S, et al. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J Hepatol. 2015;63:679–688.
  • Piersma B, Bank RA, Boersema M. Signaling in fibrosis: TGF-β, WNT, and YAP/TAZ converge. Front Med (Lausanne). 2015;2:59.
  • Chung E, De Young L, Solomon M, et al. Peyronie's disease and mechanotransduction: an in vitro analysis of the cellular changes to Peyronie's disease in a cell-culture strain system. J Sex Med. 2013;10:1259–1267.
  • Bazin S, Le Lous M, Duance VC, et al. Biochemistry and histology of the connective tissue of Dupuytren's disease lesions. Eur J Clin Invest. 1980;10:9–16.
  • Gelberman RH, Amiel D, Rudolph RM, et al. Dupuytren's contracture. An electron microscopic, biochemical, and clinical correlative study. J Bone Joint Surg Am. 1980;62:425–432.
  • Brickley-Parsons D, Glimcher MJ, Smith RJ, et al. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease. J Bone Joint Surg Am. 1981;63:787–797.
  • Hanyu T, Tajima T, Takagi T, et al. Biochemical studies on the collagen of the palmar aponeurosis affected with Dupuytren's disease. Tohoku J Exp Med. 1984;142:437–443.
  • Notbohm H, Bigi A, Roveri N, et al. Ultrastructural and biochemical modifications of collagen from tissue of Morbus Dupuytren patients. J Biochem. 1995;118:405–410.
  • Melling M, Karimian-Teherani D, Mostler S, et al. Changes of biochemical and biomechanical properties in Dupuytren disease. Arch Pathol Lab Med. 2000;124:1275–1281.
  • Han S, Makareeva E, Kuznetsova NV, et al. Molecular mechanism of type I collagen homotrimer resistance to mammalian collagenases. J Biol Chem. 2010;285:22276–22281.
  • Weis MA, Hudson DM, Kim L, et al. Location of 3-hydroxyproline residues in collagen types I, II, III, and V/XI implies a role in fibril supramolecular assembly. J Biol Chem. 2010;285:2580–2590.
  • Wenstrup RJ, Florer JB, Brunskill EW, et al. Type V collagen controls the initiation of collagen fibril assembly. J Biol Chem. 2004;279:53331–53337.
  • Gentile V, Modesti A, La Pera G, et al. Ultrastructural and immunohistochemical characterization of the tunica albuginea in Peyronie's disease and veno-occlusive dysfunction. J Androl. 1996;17:96–103.
  • Myllyharju J, Kivirikko KI. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet. 2004;20:33–43.
  • van den Bos T, Speijer D, Bank RA, et al. Differences in matrix composition between calvaria and long bone in mice suggest differences in biomechanical properties and resorption: special emphasis on collagen. Bone. 2008;43:459–468.
  • Ricard-Blum S, Bresson-Hadni S, Vuitton DA, et al. Hydroxypyridinium collagen cross-links in human liver fibrosis: study of alveolar echinococcosis. Hepatology. 1992;15:599–602.
  • van der Slot-Verhoeven AJ, van Dura EA, Attema J, et al. The type of collagen cross-link determines the reversibility of experimental skin fibrosis. Biochim Biophys Acta. 2005;1740:60–67.